The Phase 3 randomized controlled trial of sac-TMT plus PD-1 blockade, conducted exclusively in China, achieved a striking 65% reduction in progression risk for advanced non-small cell lung cancer—yet the STAT report underplays key limitations. As an RCT it carries higher internal validity than prior observational ADC series, but the undisclosed sample size and short follow-up leave overall survival immature. Prior KEYNOTE-189 and IMpower150 data established PD-1/chemotherapy backbones; this study is the first to replace cytotoxic chemotherapy with a Trop-2-directed ADC, potentially sparing patients neuropathy while maintaining efficacy. However, China-only enrollment raises questions about ethnic pharmacogenomic differences and regulatory extrapolation to Western populations. Merck’s global development plan, referenced in ASCO abstracts and concurrent phase 3 trials outside Asia (e.g., NCT05812345), will be decisive. Conflicts of interest are material: Kelun-Biotech holds the Chinese rights while Merck funds pivotal studies, creating incentive to accelerate filings before mature survival data mature.